newsfilter
← Latest News
Business Wire·

Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026

Podium presentation on NeXT Personal® monitoring neoadjuvant therapy in colorectal cancer; Real-world data from 10,000 patients reinforce industry-leading sensitivity; Data presented for a new NeXT Personal